GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncorus Inc (OTCPK:ONCR) » Definitions » Earnings per Share (Diluted)

Oncorus (Oncorus) Earnings per Share (Diluted) : $-3.49 (TTM As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Oncorus Earnings per Share (Diluted)?

Oncorus's Earnings per Share (Diluted) for the three months ended in Mar. 2023 was $-1.18. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.49.

Oncorus's EPS (Basic) for the three months ended in Mar. 2023 was $-1.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.49.

Oncorus's EPS without NRI for the three months ended in Mar. 2023 was $-0.62. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-2.93.


Oncorus Earnings per Share (Diluted) Historical Data

The historical data trend for Oncorus's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncorus Earnings per Share (Diluted) Chart

Oncorus Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
-1.98 -2.80 -9.35 -2.56 -2.99

Oncorus Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -0.74 -0.76 -0.81 -1.18

Competitive Comparison of Oncorus's Earnings per Share (Diluted)

For the Biotechnology subindustry, Oncorus's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncorus's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncorus's PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncorus's PE Ratio falls into.



Oncorus Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Oncorus's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-77.422-0)/25.924
=-2.99

Oncorus's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (Q: Mar. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-30.899-0)/26.095
=-1.18

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Oncorus  (OTCPK:ONCR) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Oncorus Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Oncorus's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncorus (Oncorus) Business Description

Industry
Traded in Other Exchanges
N/A
Address
4 Corporate Drive, Andover, MA, USA, 01810
Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Executives
Brian J. Shea officer: Interim CEO C/O ONCORUS, INC., 4 CORPORATE DRIVE, ANDOVER MA 01810
Alexander Nolte officer: Interim CFO 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
James E Flynn director, 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas Fambrough director C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON MA 02421
Rick Wanstall officer: CFO and Treasurer C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Stephen Harbin officer: COO and Chief of Staff C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Eric Rubin director C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Christophe Queva officer: CSO and SVP, Research C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE MA 02139
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Luke Evnin director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Sunstates Fund Llc 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Ansbert Gadicke 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116